Press Release

PhRMA Elects New Member to Board of Directors

PhRMA April 22, 2013

Washington, D.C. (April 22, 2013)

— The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the election of Orexigen Therapeutics President and CEO Michael A. Narachi to its Board of Directors.

“I am pleased to welcome a respected industry leader, Mike Narachi, to PhRMA’s Board of Directors,” said PhRMA President and CEO John J. Castellani. “Mike’s many years of experience in the biopharmaceutical sector make him an invaluable addition to our Board as we continue to advocate for public policies that recognize the true value of innovative medicines for both patients and the American economy.”

Mr. Narachi has served as President and CEO and a member of the Board of Directors at Orexigen Therapeutics since March 2009.

“No other industry on earth so frequently improves so many lives,” Mr. Narachi said.  “I’m proud to join the Board of PhRMA, and I look forward to helping ensure that our industry continues to make good on our commitment to patients, doctors and caregivers everywhere.”

Before joining Orexigen, Mr. Narachi served as Chairman, CEO and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009, and chairman of the Board of Directors of Naryx Pharma, Inc., a private pharmaceutical company.

In 2004, Mr. Narachi left Amgen Inc., a leading therapeutics company, where he served as an officer and Vice President and, from 1999 through 2003, as General Manager of Amgen's anemia business. After joining Amgen in 1984, he held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development.

Mr. Narachi also currently serves as a member of the Board of Directors of BIO, the Biotechnology Industry Organization, and AMAG Pharmaceuticals, Inc., a publicly traded pharmaceutical company.


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:
For information on ensuring the flow of medicines during public health emergencies, visit